A Phase 1/2 interventional study of TRI-611 in ALK-positive NSCLC, ALK-Positive Lung Cancer and ALK-positive Non-small Cell Lung Cancer, sponsored by TRIANA Biomedicines, Inc.. Recruiting at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by TRIANA Biomedicines, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 752nd largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 131 that started in 2026, is one of 486 in phase 1/2, reaches primary completion later than 718 of the 892 other live ones, and was the 3,287th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,371 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,413 · Phase 2 1,594 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 131 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 2,998 interventional studies, 100 across the 246 observational. Of the 2,300 that completed or were terminated, 1,053 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,739 of 3,371 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with TRIANA Biomedicines, Inc. as lead sponsor.
TRIANA Biomedicines, Inc. has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
269 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987956Phase 3Medicine Invention Design, IncPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
Add all 269 to your calendar (.ics) → With an account.
Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC.
The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received.
In this study participants will:
This is a Phase 1/2 dose escalation and dose expansion study designed to evaluate the safety and tolerability of TRI-611, identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in participants with ALK-positive NSCLC.
Part 1 of the study consists of a dose escalation to determine the MTD and/or recommended dose(s) of TRI-611 for further exploration in two backfill cohorts.
Following completion of Part 1 of the study, Part 2 of the study will be initiated. The second part of the study is comprised of three cohorts (M1, M2, M3) of participants differentiated based on their previous treatment with ALK TKIs (tyrosine kinase inhibitors). During this part of the study the antitumor activity of TRI-611 will be further explored. See eligibility criteria for more details.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line
Drug: TRI-611
Prior treatment with ALK TKIs, including lorlatinib. Prior treatment with neladalkib is excluded
Drug: TRI-611
Prior treatment with ALK TKIs, including lorlatinib. Prior treatment with neladalkib is required
Drug: TRI-611
Participants without prior ALK TKI treatment
Drug: TRI-611
oral ALK molecular glue degrader
Part 1: Treatment emergent adverse events
Treatment emergent adverse events (TEAEs)
Time frame: Within 28 days of the first TRI-611 dose
Part 2: Objective response rate (ORR)
Determine the objective response rate (ORR) based on RECIST v1.1
Time frame: Approximately 16 weeks after the last participant dosed in Part 2
Part 2: Depth of response (DofR)
Defined as the greatest percentage reduction in the sum of diameters of target lesions from baseline
Time frame: Approximately 16 weeks after the last participant dosed in Part 2
Part 1: Half-life (t1/2) of TRI-611
Determine the t1/2 of TRI-611
Time frame: Pre-dose and up to 24 hours post-dose
Part 1: Area under the curve (AUC) of TRI-611
Determine the AUC of TRI-611
Time frame: Pre-dose and up to 24 hours post-dose
Part 1: Maximum plasma concentration (Cmax) of TRI-611
Determine the Cmax of TRI-611
Time frame: Pre-dose and up to 24 hours post-dose
Part 1: Minimum plasma concentration (Cmin) of TRI-611
Determine the Cmin of TRI-611
Time frame: Pre-dose and up to 24 hours post-dose
Part 1: ORR
Determine the ORR based on RECIST v1.1
Time frame: Approximately 16 weeks after the last participant dosed in Part 1
Part 1: DofR
Defined as the greatest percentage reduction in the sum of diameters of target lesions from baseline
Time frame: Approximately 16 weeks after the last participant dosed in Part 1
Parts 1&2: Duration of response (DOR)
Determine the DOR based on RECIST v1.1
Time frame: Approximately 5 years after the last participant is dosed with TRI-611
Parts 1&2: Disease control rate (DCR)
Defined as the number and percentage of participants who have achieved a response or stable disease based on RECIST v1.1
Time frame: Approximately 16 weeks after the last participant dosed
Parts 1&2: Clinical Benefit Rate (CBR)
Defined as the number and percentage of participants who have achieved a response or stable disease based on RECIST v1.1 maintained for a minimum of 6 months
Time frame: Approximately 9 months after the last participant is dosed
Parts 1&2: Progression-free survival (PFS)
Determine PFS based on RECIST v1.1
Time frame: Approximately 5 years after the last participant is dosed with TRI-611
Parts 1&2: Overall survival (OS)
Determine OS based on RECIST v1.1
Time frame: Approximately 5 years after the last participant is dosed with TRI-611
Parts 1&2: Central Nervous System (CNS) objective response rate (ORR)
Determine CNS ORR based on modified RECIST (mRECIST v1.1) in participants with CNS metastasis at baseline
Time frame: Approximately 16 weeks after the last participant dosed
Parts 1&2: CNS duration of response (DOR)
Determine CNS DOR based on mRECIST v1.1 in participants with CNS metastasis at baseline
Time frame: Approximately 5 years after the last participant is dosed with TRI-611
Parts 1&2: Time to intracranial progression (TTP)
Defined as the time to the date of the first documentation of objective progression of intracranial disease
Time frame: Approximately 5 years after the last participant is dosed with TRI-611
Part 1: Profile changes in tumor ALK-fusion protein levels
Assessing treatment-induced modulation of ALK expression only in participants consenting to on-treatment biopsies
Time frame: Approximately 14 days after the last dose of participants in Part 1 that have consented to on-treatment biopsies
Started Mar 2026 (actual). Primary completion is estimated for May 2029, 38 months after the start.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 38 months is below that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →